Opdualag (Nivolumab And Relatlimab-Rmbw) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Opdualag. Always confirm against the full prescribing information.
100 interactions
Articaine
The risk or severity of methemoglobinemia can be increased when Relatlimab is combined with Articaine.
Level 1 evidence
Articaine
The risk or severity of methemoglobinemia can be increased when Nivolumab is combined with Articaine.
Level 1 evidence
Benzocaine
The risk or severity of methemoglobinemia can be increased when Relatlimab is combined with Benzocaine.
Level 1 evidence
Benzocaine
The risk or severity of methemoglobinemia can be increased when Nivolumab is combined with Benzocaine.
Level 1 evidence
Benzyl alcohol
The risk or severity of methemoglobinemia can be increased when Nivolumab is combined with Benzyl alcohol.
Level 1 evidence
Benzyl alcohol
The risk or severity of methemoglobinemia can be increased when Relatlimab is combined with Benzyl alcohol.
Level 1 evidence
Bupivacaine
The risk or severity of methemoglobinemia can be increased when Relatlimab is combined with Bupivacaine.
Level 1 evidence
Bupivacaine
The risk or severity of methemoglobinemia can be increased when Nivolumab is combined with Bupivacaine.
Level 1 evidence
Butamben
The risk or severity of methemoglobinemia can be increased when Nivolumab is combined with Butamben.
Level 1 evidence
Butamben
The risk or severity of methemoglobinemia can be increased when Relatlimab is combined with Butamben.
Level 1 evidence
Capsaicin
The risk or severity of methemoglobinemia can be increased when Nivolumab is combined with Capsaicin.
Level 1 evidence
Capsaicin
The risk or severity of methemoglobinemia can be increased when Relatlimab is combined with Capsaicin.
Opdualag (Nivolumab And Relatlimab-Rmbw) has 374 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Opdualag (Nivolumab And Relatlimab-Rmbw) has 0 major, 54 moderate, and 320 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Opdualag. Always confirm against the full prescribing information.